ProfileGDS5678 / 1460338_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 87% 85% 91% 87% 87% 89% 89% 89% 84% 86% 88% 85% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2167184
GSM967853U87-EV human glioblastoma xenograft - Control 26.6687
GSM967854U87-EV human glioblastoma xenograft - Control 36.3789785
GSM967855U87-EV human glioblastoma xenograft - Control 47.5869391
GSM967856U87-EV human glioblastoma xenograft - Control 56.7710387
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4874487
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.8035589
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.0052989
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.9284289
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3286184
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4289986
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9922288
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3459385
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5667386